Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy.

patientswithelevatedcalcitoninlevelswerefoundtohavedifferentiatedthyroidcarcinoma,whichmightbeexplainedbyCcellhyperplasiaadjacenttoafollicularorpapillarycarcinoma.Wewouldliketoaddanotherunexpectedyieldofserumcalcitoninmeasurement:thepossi-bilityofconcurrentmedullaryandpapillarythyroidcarcinomas.Weherereportacaseof59-yr-oldwomanpresentingwithright thyroid nodule. She had no family history of thyroid diseases. Both serum calcitonin and carcinoembryonic antigen (CEA) levels were in-creased (2000 pg/mL and 14.3 ng/mL, respectively), whereas thyro-globulinwasnormal(11.5ng/mL).Furtherexaminations,includingfineneedleaspirationand 131 I-meta-iodobenzylguanidine scintigraphy, in-dicated a diagnosis of medullary thyroid carcinoma, and total thyroid- ectomy with bilateral central and right modified neck dissection was performed. Both serum calcitonin and CEA levels decreased to normal range after the operation. Pathological examinations of the resected specimen showed several foci of follicles with ground glass-like nucleus, which were surrounded by medullary carcinoma tissue. Both intrathy-roidal lesion and metastatic lymph node tissue showed positive staining for both thyroglobulin and calcitonin. Therefore the diagnosis of concurrent medullary and papillary carcinomas was made. Coexistence of medullary and papillary carcinomas has been,

[1]  A. Colao,et al.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. , 1997, The Journal of clinical endocrinology and metabolism.

[2]  A. Barlier,et al.  Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. , 1996, European journal of endocrinology.

[3]  M. Vance,et al.  Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. , 1996, The Journal of clinical endocrinology and metabolism.

[4]  J. Donckier,et al.  Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. , 1996, European journal of endocrinology.

[5]  C. Nappi,et al.  Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. , 1994, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  A. Colao,et al.  Clinical management of prolactinomas: A ten-year experience , 1992, Medical oncology and tumor pharmacotherapy.

[7]  A. Paracchi,et al.  Cabergoline in the long-term therapy of hyperprolactinemic disorders. , 1992, Acta endocrinologica.